Skip to content
DataLookout
Menu

NCT05283330

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 11 versions: 10 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 26 words Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Secondary endpoints: details revised at 7 of 12 entries
    • Site details revised at 8 of 8 sites
    • Publications: details revised at 2 of 2 entries
  2. Notable Sponsor changed: Orano Med LLC to Orano Med Theranostics, SAS
    • Trial sites expanded: 4 → 8 locations
    v10
  3. Minor Site details revised at 1 of 4 sitesv9
  4. Notable Eligibility criteria shortened, about 294 wordsv7 Show 5 more changesShow less
    • Enrollment target: 55 to 48
    • Primary completion date: Aug 2026 to Jan 2027
    • Study completion date: Aug 2027 to May 2032
    • Secondary endpoints: 7 to 12
    • Study description shortened, about 7 words
  5. Notable Enrollment target: 30 to 55v6 Show 5 more changesShow less
    • Primary completion date: Aug 2024 to Aug 2026
    • Eligibility criteria expanded, about 589 words
    • Study completion date: Jan 2025 to Aug 2027
    • Secondary endpoints: details revised at 1 of 7 entries
    • Study description expanded, about 28 words
Show 4 earlier versionsHide 4 earlier versions
  1. Notable Enrollment target: 50 to 30
    • Eligibility criteria expanded, about 7 words
    • Study sites revised (4)
    • Study title shortened, about 1 word
    v5
  2. Minor Study sites revised (4)v4
  3. Minor Site contacts updated at 1 of 4 sitesv3
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 2022 to Dec 22, 2022
    • Study sites: 0 to 4
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

To determine the Recommended Phase 2 Dose (RP2D) of ²¹²Pb-DOTAM-GRPR1
Timeframe: 14 months

Secondary (6)

To assess the safety and tolerability of 212Pb-DOTAM-GRPR1.
To assess the safety and tolerability of 203Pb-DOTAM-GRPR1.
To assess PK of ²¹²Pb-DOTAM-GRPR1
To evaluate the preliminary antitumor activity of 212Pb-DOTAM-GRPR1.
To evaluate the preliminary antitumor activity of 212Pb-DOTAM-GRPR1
Show 1 moreShow less
To evaluate the preliminary antitumor activity of 212-PbDOTAM-GRPR1.

Arms and interventions

²¹²Pb-DOTAM-GRPR1Experimental

In the dose escalation portion, a classic 3+3 design will be utilized for the SAD cohorts and a Boin design for the MAD cohorts. Doses will be increased by approximately 30% in subsequent cohorts. The maximum total dose that may be administered to a subject per cycle is 5.5 mCi +/- 10%.

Drugs: ²¹²Pb-DOTAM-GRPR1

Sites

8 sites in 1 country